Cortés, Javier, Priego, Araceli, Garralda, Elena, Rojas, Katerin, Lord, Simon R., Goetze, Thorsten O., Kuemmel, Sherko, Crabb, Simon J., Parra-Guillen, Zinnia P., Borggren, Marie, Karlsson, Ingrid, Lindahl, Danijela, Mårtensson, Linda, Oldham, Robert, Ropenga, Anna, Teige, Ingrid, Wallin, Johan, Frendeus, Björn and McAllister, Andres (2025) A first-in-class monoclonal antibody (BI-1607) targeting FcγRIIB: preclinical data and first-in-human studies in patients with HER2-positive advanced solid tumors. Clinical Cancer Research, 31 (23), 4953-4963. (doi:10.1158/1078-0432.CCR-25-1348).
Abstract
Purpose: BI-1607 is a human monoclonal antibody that specifically blocks FcγRIIB, sole inhibitory Fc receptor and master regulator of humoral and innate immune homeostasis. These studies evaluated preclinical antitumor activity using a BI-1607 murine surrogate (mBI-1607), and safety, tolerability, pharmacokinetics, and pharmacodynamics of the compound in combination with trastuzumab in patients with HER2-positive advanced solid tumors (NCT05555251).
Patients and Methods: immunocompetent syngeneic mouse breast tumor (TUBO) and melanoma (B16-F10) models were used to evaluate in vivo antitumor activity in combination (anti-HER2 and anti-gp75). Ascending doses of BI-1607 administered intravenously every three weeks in combination with trastuzumab were evaluated in 18 HER2-positive cancer patients. The primary objective was to assess safety and tolerability of BI-1607 by determining dose-limiting toxicities, maximum tolerated dose (MTD) or maximum administered dose and identifying a recommended phase 2 dose.
Results: mBI-1607 enhanced tumor-targeting antibody efficacy and animal survival. BI-1607/trastuzumab was well tolerated, with dose-limiting toxicity (rash) in 1 patient (5.6 %) at 900 mg; the MTD was not reached. Treatment-emergent adverse events grade ≥3 occurred in 5 patients (28 %), including exanthema, increase in liver enzymes, urticaria, acute kidney injury, and aggravated condition. Overall best response was stable disease, observed in 7 out of the 9 evaluable patients (78 %). BI-1607 exhibits linear pharmacokinetics for doses above 500 mg, and full receptor saturation throughout the 21 days at 700 mg. No ADAs were observed.
Conclusions: the enhancing effect on tumor direct-targeting antibodies observed preclinically, together with the favorable safety profile in patients support further investigation of BI-1607.
More information
Identifiers
Catalogue record
Export record
Altmetrics
Contributors
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.